https://nanets.net/abstracts-archive/2022-1?format=html Tue, 13 Jun 2023 12:07:14 -0400 en-GB hourly 1 https://nanets.net/abstracts-archive/2022-1/1765-ana-de-jesus-acosta-headshot?format=html Ana De Jesus Acosta Headshot https://nanets.net/abstracts-archive/2022-1/1765-ana-de-jesus-acosta-headshot?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Tue, 13 Jun 2023 12:07:14 -0400 https://nanets.net/abstracts-archive/2022-1/1764-sushil-luis-15700607?format=html Sushil luis 15700607 https://nanets.net/abstracts-archive/2022-1/1764-sushil-luis-15700607?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Tue, 13 Jun 2023 10:00:46 -0400 https://nanets.net/abstracts-archive/2022-1/1756-p3-hu-socioeconomic-factors-treatment-modality-and-survival-in-islet-cell-carcinoma-a-national-cancer-database-analysis-1?format=html [P3] Hu - Socioeconomic Factors, Treatment Modality, and Survival in Islet Cell Carcinoma: A National Cancer Database Analysis https://nanets.net/abstracts-archive/2022-1/1756-p3-hu-socioeconomic-factors-treatment-modality-and-survival-in-islet-cell-carcinoma-a-national-cancer-database-analysis-1?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 10:47:12 -0400 https://nanets.net/abstracts-archive/2022-1/1754-t10-mohamed-pilot-study-of-tq-formula-in-combination-with-nivolumab-and-ipilimumab-in-metastatic-gastroenteropancreatic-neuroendocrine-carcinomas-gep-necas?format=html [T10] Mohamed - Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs) https://nanets.net/abstracts-archive/2022-1/1754-t10-mohamed-pilot-study-of-tq-formula-in-combination-with-nivolumab-and-ipilimumab-in-metastatic-gastroenteropancreatic-neuroendocrine-carcinomas-gep-necas?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:52:41 -0400 https://nanets.net/abstracts-archive/2022-1/1753-t9-puranik-precedent-trial-phase-iii-randomised-controlled-trial-of-prrt-with-lutetium-177-dotatate-plus-chemotherapy-versus-prrt-alone-in-fdg-avid-well-differentiated-gastro-entero-pancreatic-neuroendocrine-tumors?format=html [T9] Puranik - PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy Versus PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2022-1/1753-t9-puranik-precedent-trial-phase-iii-randomised-controlled-trial-of-prrt-with-lutetium-177-dotatate-plus-chemotherapy-versus-prrt-alone-in-fdg-avid-well-differentiated-gastro-entero-pancreatic-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:50:49 -0400 https://nanets.net/abstracts-archive/2022-1/1751-t8-chauhan-phase-ii-trial-evaluating-177lu-lu-dota-tate-in-adolescents-with-somatostatin-receptor-sstr-positive-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pheochromocytomas-and-paragangliomas-ppgls?format=html [T8] Chauhan - Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)- positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs) https://nanets.net/abstracts-archive/2022-1/1751-t8-chauhan-phase-ii-trial-evaluating-177lu-lu-dota-tate-in-adolescents-with-somatostatin-receptor-sstr-positive-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pheochromocytomas-and-paragangliomas-ppgls?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:49:26 -0400 https://nanets.net/abstracts-archive/2022-1/1750-t7-singh-methodology-of-the-sorento-clinical-trial-assessing-efficacy-and-safety-of-high-exposure-octreotide-subcutaneous-depot-in-patients-with-gep-net?format=html [T7] Singh - Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET https://nanets.net/abstracts-archive/2022-1/1750-t7-singh-methodology-of-the-sorento-clinical-trial-assessing-efficacy-and-safety-of-high-exposure-octreotide-subcutaneous-depot-in-patients-with-gep-net?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:46:48 -0400 https://nanets.net/abstracts-archive/2022-1/1749-t6-hope-action-1-a-randomized-phase-ib-3-trial-of-ryz101-compared-with-soc-in-sstr2-well-differentiated-gep-net-with-progression-following-lu-177-ssa?format=html [T6] Hope - ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA https://nanets.net/abstracts-archive/2022-1/1749-t6-hope-action-1-a-randomized-phase-ib-3-trial-of-ryz101-compared-with-soc-in-sstr2-well-differentiated-gep-net-with-progression-following-lu-177-ssa?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:45:21 -0400 https://nanets.net/abstracts-archive/2022-1/1748-t5-jimenez-a-phase-2-open-label-study-of-belzutifan-a-hif-2-inhibitor-monotherapy-in-patients-with-advanced-metastatic-pheochromocytoma-paraganglioma-or-pancreatic-neuroendocrine-tumors?format=html [T5] Jimenez - A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/ Paraganglioma or Pancreatic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2022-1/1748-t5-jimenez-a-phase-2-open-label-study-of-belzutifan-a-hif-2-inhibitor-monotherapy-in-patients-with-advanced-metastatic-pheochromocytoma-paraganglioma-or-pancreatic-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:44:20 -0400 https://nanets.net/abstracts-archive/2022-1/1747-t4-mcgarrah-phase-1-2-trial-of-vesicular-stomatitis-virus-expressing-human-interferon-and-nis-vsvifn-nis-with-pembrolizumab-in-patients-with-neuroendocrine-carcinoma?format=html [T4] McGarrah - Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSVIFNβ- NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma https://nanets.net/abstracts-archive/2022-1/1747-t4-mcgarrah-phase-1-2-trial-of-vesicular-stomatitis-virus-expressing-human-interferon-and-nis-vsvifn-nis-with-pembrolizumab-in-patients-with-neuroendocrine-carcinoma?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:43:14 -0400 https://nanets.net/abstracts-archive/2022-1/1746-t3-chauhan-phase-2-study-to-evaluate-the-safety-pharmacokinetics-and-dose-response-of-paltusotine-carcinoid-syndrome?format=html [T3] Chauhan - Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome https://nanets.net/abstracts-archive/2022-1/1746-t3-chauhan-phase-2-study-to-evaluate-the-safety-pharmacokinetics-and-dose-response-of-paltusotine-carcinoid-syndrome?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:41:52 -0400 https://nanets.net/abstracts-archive/2022-1/1745-t2-halfdanarson-compose-pivotal-phase-iii-trial-for-well-differentiated-aggressive-grade-2-3-gastroenteropancreatic-neuroendocrine-tumors-comparing-177lu-edotreotide-with-best-standard-of-care?format=html [T2] Halfdanarson - COMPOSE: Pivotal Phase III Trial for Well- Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care https://nanets.net/abstracts-archive/2022-1/1745-t2-halfdanarson-compose-pivotal-phase-iii-trial-for-well-differentiated-aggressive-grade-2-3-gastroenteropancreatic-neuroendocrine-tumors-comparing-177lu-edotreotide-with-best-standard-of-care?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:38:28 -0400 https://nanets.net/abstracts-archive/2022-1/1744-t1-stockton-phase-ia-ib-study-of-bay1895344-plus-topoisomerase-i-inhibitors-with-a-focus-on-poorly-differentiated-neuroendocrine-carcinomas-and-pancreatic-adenocarcinoma?format=html [T1] Stockton - Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma https://nanets.net/abstracts-archive/2022-1/1744-t1-stockton-phase-ia-ib-study-of-bay1895344-plus-topoisomerase-i-inhibitors-with-a-focus-on-poorly-differentiated-neuroendocrine-carcinomas-and-pancreatic-adenocarcinoma?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:37:06 -0400 https://nanets.net/abstracts-archive/2022-1/1743-p10-ituarte-environmental-pollution-and-gep-nens-is-there-an-association?format=html [P10] Ituarte - Environmental Pollution and GEP-NENS – Is There an Association? https://nanets.net/abstracts-archive/2022-1/1743-p10-ituarte-environmental-pollution-and-gep-nens-is-there-an-association?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:34:51 -0400 https://nanets.net/abstracts-archive/2022-1/1742-p9-bogaards-lifestyle-and-neuro-endocrine-tumor-net-development-within-the-european-prospective-investigation-into-cancer-and-nutrition-epic-cohort?format=html [P9] Bogaards - Lifestyle and Neuro-endocrine Tumor (NET) Development Within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort https://nanets.net/abstracts-archive/2022-1/1742-p9-bogaards-lifestyle-and-neuro-endocrine-tumor-net-development-within-the-european-prospective-investigation-into-cancer-and-nutrition-epic-cohort?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:33:01 -0400 https://nanets.net/abstracts-archive/2022-1/1741-p8-hernandez-multivisceral-surgical-resection-of-locally-advanced-pancreatic-neuroendocrine-tumor-is-associated-with-a-survival-benefit?format=html [P8] Hernandez - Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit https://nanets.net/abstracts-archive/2022-1/1741-p8-hernandez-multivisceral-surgical-resection-of-locally-advanced-pancreatic-neuroendocrine-tumor-is-associated-with-a-survival-benefit?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:31:20 -0400 https://nanets.net/abstracts-archive/2022-1/1740-p7-mulvey-feasibility-of-e-net-a-web-based-health-platform-to-investigate-quality-of-life-in-patients-with-neuroendocrine-tumors?format=html [P7] Mulvey - Feasibility of e-NET: A Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors https://nanets.net/abstracts-archive/2022-1/1740-p7-mulvey-feasibility-of-e-net-a-web-based-health-platform-to-investigate-quality-of-life-in-patients-with-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:30:18 -0400 https://nanets.net/abstracts-archive/2022-1/1739-p6-ackbarali-evaluating-the-impact-of-education-on-clinician-integration-of-guidelines-real-world-data-and-patient-perspectives-on-gastroenteropancreatic-neuroendocrine-tumors-gep-nets?format=html [P6] Ackbarali - Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) https://nanets.net/abstracts-archive/2022-1/1739-p6-ackbarali-evaluating-the-impact-of-education-on-clinician-integration-of-guidelines-real-world-data-and-patient-perspectives-on-gastroenteropancreatic-neuroendocrine-tumors-gep-nets?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:28:58 -0400 https://nanets.net/abstracts-archive/2022-1/1738-p5-laderian-comparison-of-demographics-and-overall-survival-os-among-patients-with-young-onset-yo-and-late-onset-lo-gi-neuroendocrine-tumors-carcinomas-nets-necs-in-the-united-states?format=html [P5] Laderian - Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late- Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States https://nanets.net/abstracts-archive/2022-1/1738-p5-laderian-comparison-of-demographics-and-overall-survival-os-among-patients-with-young-onset-yo-and-late-onset-lo-gi-neuroendocrine-tumors-carcinomas-nets-necs-in-the-united-states?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sun, 23 Oct 2022 09:27:38 -0400 https://nanets.net/abstracts-archive/2022-1/1735-p2-chu-factors-impacting-survival-outcomes-of-islet-cell-carcinoma?format=html [P2] Chu - Factors Impacting Survival Outcomes of Islet Cell Carcinoma https://nanets.net/abstracts-archive/2022-1/1735-p2-chu-factors-impacting-survival-outcomes-of-islet-cell-carcinoma?format=html wertherm@adgcommunications.com (Maureen Werther) 2022 Sat, 22 Oct 2022 17:36:38 -0400